Cognition Therapeutics, Inc. announced today the results of a pre-specified analysis from its Phase 2 SHINE study of CT1812 in mild-to-moderate Alzheimer’s disease, presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Participants treated with CT1812 who had baseline plasma p-tau217 below the median experienced a 95% slowing of cognitive decline as measured by ADAS-Cog 11.
The same subgroup of patients also showed a 108% slowing of cognitive decline when measured by the MMSE scale, while placebo patients in both analyses experienced cognitive decline. Plasma p-tau217 is an important biomarker that can distinguish Alzheimer’s disease from other neurodegenerative disorders with high accuracy.
These findings suggest that plasma p-tau217 could serve as a predictive biomarker for robust treatment effect, enabling the company to identify patients most likely to benefit from CT1812. Cognition Therapeutics plans to discuss these results and potential approaches for a Phase 3 program with the FDA in an upcoming end-of-Phase 2 meeting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.